NYSE:NVRO - Nevro Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $199.90
  • Forecasted Upside: 22.71 %
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$162.91
▲ +2.46 (1.53%)

This chart shows the closing price for NVRO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nevro Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVRO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVRO

Analyst Price Target is $199.90
▲ +22.71% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Nevro in the last 3 months. The average price target is $199.90, with a high forecast of $225.00 and a low forecast of $160.00. The average price target represents a 22.71% upside from the last price of $162.91.

This chart shows the closing price for NVRO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in Nevro. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021Canaccord GenuityBoost Price TargetBuy$217.00 ➝ $225.00High
3/4/2021SVB LeerinkReiterated RatingBuyHigh
2/26/2021Morgan StanleyBoost Price TargetOverweight$192.00 ➝ $199.00Low
2/25/2021Canaccord GenuityBoost Price TargetBuy$203.00 ➝ $217.00Medium
2/2/2021Piper SandlerInitiated CoverageOverweight$190.00N/A
1/19/2021Canaccord GenuityBoost Price TargetBuy$167.00 ➝ $203.00Medium
1/19/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$190.00 ➝ $210.00Medium
1/6/2021TruistBoost Price Target$175.00 ➝ $205.00N/A
1/5/2021Robert W. BairdBoost Price TargetOutperform$180.00 ➝ $200.00N/A
1/4/2021Wells Fargo & CompanyBoost Price TargetOverweight$177.00 ➝ $215.00N/A
12/31/2020GuggenheimBoost Price TargetBuy$190.00 ➝ $205.00N/A
12/15/2020Morgan StanleyBoost Price TargetOverweight$161.00 ➝ $192.00Medium
11/11/2020JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $190.00Low
11/6/2020Morgan StanleyBoost Price TargetOverweight$150.00 ➝ $161.00Low
10/22/2020GuggenheimInitiated CoverageBuy$190.00Low
10/21/2020OTR GlobalUpgradePositiveLow
10/12/2020SVB LeerinkBoost Price TargetOutperform$165.00 ➝ $175.00Low
9/1/2020Robert W. BairdInitiated CoverageOutperform$160.00Low
8/6/2020Canaccord GenuityBoost Price TargetBuy$116.00 ➝ $153.00Medium
8/6/2020Morgan StanleyBoost Price TargetOverweight$145.00 ➝ $150.00Medium
8/6/2020Wells Fargo & CompanyBoost Price TargetOverweight$141.00 ➝ $153.00High
8/6/2020SVB LeerinkBoost Price TargetOutperform$140.00 ➝ $165.00High
8/6/2020CitigroupBoost Price TargetBuy$137.00 ➝ $160.00High
8/5/2020OppenheimerInitiated CoverageHoldHigh
6/18/2020Morgan StanleyBoost Price Target$135.00 ➝ $145.00High
6/18/2020CitigroupBoost Price TargetOverweight$135.00 ➝ $145.00High
6/8/2020UBS GroupUpgradeSell ➝ Neutral$100.00 ➝ $132.00High
6/4/2020SunTrust BanksReiterated RatingBuy$135.00High
5/6/2020SunTrust BanksBoost Price TargetBuy$120.00 ➝ $135.00Medium
5/6/2020Morgan StanleyBoost Price TargetOverweight$113.00 ➝ $135.00Medium
5/6/2020JPMorgan Chase & Co.Boost Price TargetNeutral$90.00 ➝ $100.00Low
5/6/2020CitigroupBoost Price TargetBuy$130.00 ➝ $137.00Low
4/3/2020Morgan StanleyLower Price TargetOverweight$118.00 ➝ $113.00Low
4/2/2020JPMorgan Chase & Co.Lower Price TargetNeutral$130.00 ➝ $90.00High
4/2/2020Canaccord GenuityLower Price TargetBuy$153.00 ➝ $114.00High
4/2/2020SunTrust BanksLower Price TargetBuy$146.00 ➝ $120.00High
4/2/2020Wells Fargo & CompanyLower Price TargetOverweight$158.00 ➝ $126.00High
3/27/2020Morgan StanleyLower Price TargetOverweight$142.00 ➝ $118.00Low
3/27/2020CitigroupLower Price TargetBuy$160.00 ➝ $130.00High
3/4/2020CitigroupInitiated CoverageBuy$160.00Low
2/26/2020SVB LeerinkBoost Price TargetOutperform ➝ Positive$146.00 ➝ $158.00High
2/26/2020Wells Fargo & CompanyBoost Price TargetOverweight$144.00 ➝ $158.00High
2/26/2020JPMorgan Chase & Co.Boost Price TargetNeutral$96.00 ➝ $130.00High
2/26/2020Canaccord GenuityUpgradeHold ➝ Buy$120.00 ➝ $153.00High
1/27/2020Morgan StanleyBoost Price TargetOverweight$125.00 ➝ $142.00High
1/27/2020JMP SecuritiesBoost Price TargetOutperform$115.00 ➝ $150.00High
1/21/2020Wells Fargo & CompanyBoost Price TargetOverweight$135.00 ➝ $144.00Low
1/15/2020UBS GroupBoost Price TargetSell$77.00 ➝ $84.00High
1/7/2020SunTrust BanksInitiated CoverageBuy$132.00Low
1/6/2020OppenheimerReiterated RatingOutperform ➝ Market PerformN/A
12/20/2019JPMorgan Chase & Co.Boost Price TargetNeutral$80.00 ➝ $96.00Low
12/17/2019Morgan StanleyBoost Price TargetOverweight$100.00 ➝ $125.00Low
11/7/2019Canaccord GenuityBoost Price TargetHold ➝ Hold$59.00 ➝ $88.00High
11/7/2019OppenheimerUpgradeMarket Perform ➝ Outperform$106.00High
11/7/2019Wells Fargo & CompanyBoost Price TargetOutperform$86.00 ➝ $105.00High
11/7/2019JMP SecuritiesBoost Price TargetOutperform$115.00High
10/22/2019OppenheimerInitiated CoverageMarket PerformHigh
10/9/2019Wells Fargo & CompanyBoost Price TargetOutperform$70.00 ➝ $86.00Low
8/23/2019SVB LeerinkSet Price TargetBuy$98.00Medium
8/12/2019JMP SecuritiesBoost Price TargetMarket Outperform$70.00 ➝ $90.00High
8/9/2019Morgan StanleySet Price TargetBuy$76.00Medium
8/9/2019Northland SecuritiesSet Price TargetHold$65.00Medium
8/9/2019Bank of AmericaBoost Price TargetBuy$70.00 ➝ $74.00N/A
8/9/2019Canaccord GenuityBoost Price TargetHold$50.00 ➝ $59.00High
5/13/2019Wells Fargo & CompanyLower Price TargetOutperform$75.00 ➝ $70.00Low
5/10/2019Morgan StanleyLower Price TargetOverweight$70.00 ➝ $64.00High
5/10/2019JMP SecuritiesLower Price TargetMarket Outperform$80.00 ➝ $70.00High
5/10/2019Canaccord GenuityDowngradeBuy ➝ Hold$62.00 ➝ $50.00High
3/20/2019Morgan StanleyUpgradeUnderweight ➝ Overweight$41.00 ➝ $70.00High
3/20/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$75.00High
3/20/2019Canaccord GenuityBoost Price TargetBuy$46.00 ➝ $62.00High
3/20/2019Bank of AmericaUpgradeNeutral ➝ Buy$50.00 ➝ $70.00High
3/19/2019BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$46.00 ➝ $67.00High
2/22/2019BMO Capital MarketsDowngradeOutperform ➝ Market PerformHigh
1/11/2019Northland SecuritiesReiterated RatingHold$48.00Low
1/2/2019Morgan StanleyLower Price TargetUnderweight ➝ Underweight$43.00 ➝ $38.00High
11/27/2018UBS GroupInitiated CoverageSell ➝ Sell$35.00Low
11/7/2018Bank of AmericaDowngradeBuy ➝ NeutralHigh
11/6/2018Morgan StanleyDowngradeEqual ➝ Equal Weight$65.00 ➝ $43.00High
11/6/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$76.00 ➝ $60.00High
11/6/2018Canaccord GenuityLower Price TargetBuy ➝ In-Line$80.00 ➝ $63.00High
11/6/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$62.00 ➝ $50.00High
11/6/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$77.00 ➝ $45.00High
10/19/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$60.00 ➝ $44.00High
8/6/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$80.00 ➝ $76.00High
7/17/2018Bank of AmericaLower Price TargetBuy ➝ Buy$102.00 ➝ $77.00Low
7/17/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$84.00 ➝ $62.00Low
7/17/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$95.00 ➝ $90.00Low
7/17/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$88.00 ➝ $65.00Low
7/16/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$102.00 ➝ $83.00High
7/11/2018JPMorgan Chase & Co.Reiterated RatingBuyLow
7/2/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00High
5/8/2018Canaccord GenuityLower Price TargetBuy ➝ Buy$110.00 ➝ $102.00High
5/8/2018JMP SecuritiesReiterated RatingMarket Outperform ➝ Overweight$120.00 ➝ $105.00High
5/8/2018Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
5/8/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
4/4/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$83.00Low
12/14/2017BMO Capital MarketsReiterated RatingBuy$100.00High
11/7/2017Canaccord GenuityLower Price TargetBuy$120.00 ➝ $110.00N/A
11/7/2017Northland SecuritiesReiterated RatingBuy$96.00N/A
11/7/2017SVB LeerinkReiterated RatingOutperform$105.00 ➝ $110.00N/A
10/8/2017Canaccord GenuityReiterated RatingBuy$120.00N/A
9/1/2017BMO Capital MarketsReiterated RatingBuy$106.00N/A
8/8/2017Northland SecuritiesReiterated RatingBuy$96.00High
8/8/2017Morgan StanleyBoost Price TargetOverweight$87.00 ➝ $95.00Medium
7/5/2017Canaccord GenuityReiterated RatingBuy$120.00High
7/3/2017JPMorgan Chase & Co.Reiterated RatingOverweight$102.00Low
6/15/2017Northland SecuritiesSet Price TargetBuy$96.00Low
5/14/2017B. RileyDowngradeNeutral$85.00Low
5/9/2017B. RileyDowngradeBuy ➝ Neutral$108.00 ➝ $85.00High
5/9/2017Northland SecuritiesReiterated RatingBuy$96.00High
3/23/2017Canaccord GenuityInitiated CoverageBuy$120.00Medium
3/1/2017B. RileyReiterated RatingBuy$108.00N/A
2/24/2017B. RileyReiterated RatingBuy$108.00N/A
2/24/2017SVB LeerinkBoost Price TargetOutperform$100.00 ➝ $110.00N/A
2/2/2017Northland SecuritiesReiterated RatingPositive$110.00N/A
1/30/2017Northland SecuritiesUpgradeMarket Perform ➝ Outperform$110.00N/A
11/13/2016B. RileyReiterated RatingBuy$102.00N/A
11/8/2016B. RileyReiterated RatingBuy$102.00N/A
9/21/2016B. RileyInitiated CoverageBuy$114.00N/A
9/16/2016B. RileyReiterated RatingBuyN/A
9/15/2016B. RileyInitiated CoverageBuy$114.00N/A
8/11/2016Piper Jaffray CompaniesReiterated RatingOverweight$98.00 ➝ $112.00N/A
8/9/2016JPMorgan Chase & Co.Boost Price TargetOverweight$84.00 ➝ $100.00N/A
8/9/2016JMP SecuritiesBoost Price TargetMarket Outperform$90.00 ➝ $110.00N/A
8/9/2016BMO Capital MarketsReiterated RatingBuy$100.00N/A
8/8/2016Bank of AmericaInitiated CoverageBuy$100.00N/A
7/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$98.00N/A
7/19/2016William BlairInitiated CoverageOutperformN/A
7/18/2016William BlairReiterated RatingOutperformN/A
7/12/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
6/29/2016Morgan StanleyReiterated RatingBuy$86.00N/A
(Data available from 6/21/2016 forward)
Nevro logo
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $162.91
Low: $157.91
High: $163.82

50 Day Range

MA: $154.88
Low: $144.19
High: $174.83

52 Week Range

Now: $162.91
Low: $111.87
High: $188.14

Volume

311,956 shs

Average Volume

437,053 shs

Market Capitalization

$5.67 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of Nevro?

The following Wall Street research analysts have issued stock ratings on Nevro in the last year: Canaccord Genuity, Citigroup Inc., Guggenheim, JMP Securities, Morgan Stanley, Oppenheimer Holdings Inc., OTR Global, Piper Sandler, Robert W. Baird, SVB Leerink LLC, TheStreet, Truist, and Wells Fargo & Company.
View the latest analyst ratings for NVRO.

What is the current price target for Nevro?

10 Wall Street analysts have set twelve-month price targets for Nevro in the last year. Their average twelve-month price target is $199.90, suggesting a possible upside of 22.7%. Canaccord Genuity has the highest price target set, predicting NVRO will reach $225.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $160.00 for Nevro in the next year.
View the latest price targets for NVRO.

What is the current consensus analyst rating for Nevro?

Nevro currently has 1 hold rating and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVRO will outperform the market and that investors should add to their positions of Nevro.
View the latest ratings for NVRO.

What other companies compete with Nevro?

How do I contact Nevro's investor relations team?

Nevro's physical mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider's listed phone number is 650-251-0005 and its investor relations email address is [email protected] The official website for Nevro is www.nevro.com.